Pharmacokinetics and safety of dasatinib and its generic: a phase I bioequivalence study in healthy Chinese subjects-Reference-Cited by-同舟云学术

Pharmacokinetics and safety of dasatinib and its generic: a phase I bioequivalence study in healthy Chinese subjects

Published:2023-02-18 Issue:3 Volume:32 Page:263-270
ISSN:1354-3784
Container-title:Expert Opinion on Investigational Drugs
language:en
Short-container-title:Expert Opinion on Investigational Drugs

Author:

Wang Yanli¹,Xue Jinling²,Su Zhengjie¹,Cui Yingzi¹,Liu Guangwen¹,Yang Wei¹,Liu Zhengzhi¹,Chen Jiahui¹,Ren Qing¹,Yu Shuang¹,Cheng Yang¹,Zhou Yannan¹,Wang Wanhua¹,Chen Xuesong³,Qu Dongmei³,Deng Qiaohuan¹,Zhao Yicheng⁴⁵,Yang Haimiao¹

Affiliation:

1. Phase I Clinical Trial Laboratory, Affiliated Hospital of Changchun University of Chinese Medicine, Changchun, China

2. Department of clinical research center Clinical Research Center, Chia Tai Tianqing Pharmaceutical Group Co., Ltd, Nanjing, China

3. The Clinical Trial Quality Control Center, Ansiterui Medical Technology Consulting Co., Ltd, Changchun, China

4. Puheng Technology Co., Ltd, Suzhou, China

5. Clinical Medical College, Changchun University of Chinese Medicine, Changchun, China

Funder

Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Nanjing, China. Funding number is phase

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/13543784.2023.2179481

Reference35 articles.

1. Chronic Myelogenous Leukemia: Biology and Therapy

2. The Biology of Chronic Myeloid Leukemia

3. The biology of CML blast crisis

4. Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring

5. Imatinib

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dasatinib: a potential tyrosine kinase inhibitor to fight against multiple cancer malignancies;Medical Oncology;2023-05-10